Sapanisertib
http://dbpedia.org/resource/Sapanisertib an entity of type: Thing
Sapanisertib (also known as MLN0128, INK128 and TAK-228) is an experimental small molecule inhibitor of mTOR which is administered orally. It targets both mTORC1 and mTORC2. Developed by Millennium Pharmaceuticals, and is in phase II clinical trials for breast cancer, endometrial cancer, glioblastoma, renal cell carcinoma, and thyroid cancer. The drug has been well tolerated by patients with advanced solid tumours in Phase I trials.
rdf:langString
rdf:langString
Sapanisertib
xsd:integer
53048287
xsd:integer
1028184852
xsd:integer
15
xsd:integer
1224844
xsd:integer
15
xsd:integer
5
rdf:langString
D11183
xsd:integer
7
xsd:integer
1
xsd:integer
45375953
rdf:langString
CCN1C2=CCN
xsd:integer
1
rdf:langString
GYLDXIAOMVERTK-UHFFFAOYSA-N
rdf:langString
JGH0DF1U03
rdf:langString
Sapanisertib (also known as MLN0128, INK128 and TAK-228) is an experimental small molecule inhibitor of mTOR which is administered orally. It targets both mTORC1 and mTORC2. Developed by Millennium Pharmaceuticals, and is in phase II clinical trials for breast cancer, endometrial cancer, glioblastoma, renal cell carcinoma, and thyroid cancer. The drug has been well tolerated by patients with advanced solid tumours in Phase I trials.
xsd:nonNegativeInteger
5164
xsd:string
1224844-38-5
xsd:string
JGH0DF1U03
xsd:string
D11183
xsd:string
45375953